What Happened?
A number of stocks jumped in the afternoon session after the reopening of the Strait of Hormuz signaled a cooling of global logistics and energy costs.
For healthcare providers and medical device manufacturers, lower oil prices directly reduce the cost of operating large hospital facilities and shipping sensitive medical equipment. This margin relief is vital for a sector that has been squeezed by high transportation overhead, allowing for a more favorable outlook on quarterly earnings. The "risk-on" sentiment sparked by the ceasefire is also driving capital back into high-growth biotech and pharmaceutical names.
As broader market volatility recedes, investors are more willing to fund long-term R&D and clinical trials that were previously shadowed by macroeconomic uncertainty. The stabilization of the global economy ensures that both elective procedures and pharmaceutical demand remain on a steady upward trajectory for the remainder of 2026.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.
Among others, the following stocks were impacted:
- Dental Equipment & Technology company Envista (NYSE: NVST) jumped 3.5%. Is now the time to buy Envista? Access our full analysis report here, it’s free.
- Medical Devices & Supplies - Diversified company Baxter (NYSE: BAX) jumped 3.9%. Is now the time to buy Baxter? Access our full analysis report here, it’s free.
- Outpatient & Specialty Care company Surgery Partners (NASDAQ: SGRY) jumped 3.6%. Is now the time to buy Surgery Partners? Access our full analysis report here, it’s free.
- Drug Development Inputs & Services company Charles River Laboratories (NYSE: CRL) jumped 3.7%. Is now the time to buy Charles River Laboratories? Access our full analysis report here, it’s free.
- Drug Development Inputs & Services company Repligen (NASDAQ: RGEN) jumped 3.4%. Is now the time to buy Repligen? Access our full analysis report here, it’s free.
Zooming In On Baxter (BAX)
Baxter’s shares are not very volatile and have only had 8 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 9 months ago when the stock dropped 20% on the news that the company reported disappointing second-quarter results and cut its full-year profit forecast, citing the lingering impact of a hurricane.
The healthcare company pointed to the lingering effects of Hurricane Helene, which damaged a key manufacturing facility and disrupted the supply of its IV solutions. Baxter’s adjusted earnings per share of 59 cents missed analysts' estimates, while revenue of $2.81 billion also came in slightly below expectations. In response to these challenges and what management called demand softness, the company lowered its full-year profit guidance. The weak results and revised outlook prompted a negative reaction from investors.
Baxter is down 4% since the beginning of the year, and at $18.72 per share, it is trading 41.3% below its 52-week high of $31.88 from May 2025. Investors who bought $1,000 worth of Baxter’s shares 5 years ago would now be looking at only $216.31.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
